Malignant News and Research

RSS

Seroquel XR supplemental NDA recommended for approval

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) conducted a review of the safety and efficacy of supplemental new drug applications (sNDA) for Seroquel XR (quetiapine fumarate) extended-release tablets proposed for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

9 Apr 2009

Discovery of marker for colon stem cells could shed light on tumor growth

Cancer researchers led by Bruce Boman, M.D., Ph.D. director of Cancer Genetics and Stem Cell Biology at the Helen F. Graham Cancer Center of the Christiana Care Health System, and a faculty member at the University of Delaware, have discovered an enzyme common to both normal and malignant colon stem cells that will assist scientists searching for a cure for colon cancer.

8 Apr 2009

Deadly skin cancer now threatens women in their twenties

The deadliest form of skin cancer has now become the most common kind of cancer for women in their 20s - according to the latest figures from Cancer Research UK which launches its 2009 SunSmart campaign today.

7 Apr 2009

Avastin safe and effective at delaying tumor progression

The use of Avastin alone to treat a subgroup of recurrent Grade 3 brain tumors showed it was safe and effective at delaying tumor progression, according to a retrospective study of 22 patients conducted by a researcher at the Seattle Cancer Care Alliance.

6 Apr 2009

BRAF gene mutation is a crucial skin cancer switch

Up to 70 per cent of melanoma skin cancers could be triggered by a particular genetic mutation, according to a Cancer Research UK funded study published in Cancer Cell.

6 Apr 2009

Researchers at the UJI increase the efficiency of photocatalysts used in cancer treatments

Researchers at the Universitat Jaume I (UJI) in Castellon have found porous polymeric materials that increase the efficiency of traditional photocatalysts in the treatment of cancer.

6 Apr 2009

Fluorescent cancer cells to guide brain surgeons

Gliomas are malignant brain tumors that arise from glial (supporting) cells of the brain.

5 Apr 2009

Computer based model helps tell benign and malignant breast lesions apart

Radiologists have developed a computer based model that aids them in discriminating between benign and malignant breast lesions, according to a study performed at the University Of Wisconsin School of Medicine, Madison, WI.

5 Apr 2009

Neurokinin 1 receptor may prove useful in treating deadly brain tumors

Duke University researchers have identified a receptor on the surface of cells that may give them another avenue of attack against glioblastoma, the most common and most deadly type of brain cancer.

5 Apr 2009

FDA clears Cellectar's IND application for drug candidate

Cellectar, Inc., a privately held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, has announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its (131)I-CLR1404 drug candidate for testing in patients with advanced solid malignancies.

2 Apr 2009

Discovery of marker for severity in adult brain cancer

Researchers at UT Southwestern Medical Center have identified a new biological indicator that may help identify which brain-cancer patients have the most aggressive forms of the disease.

1 Apr 2009

New light-based system reveals breast tumor oxygen status

Light directed at a breast tumor through a needle can provide pathologists with biological specifics of the tumor and help oncologists choose treatment options that would be most effective for that individual patient.

1 Apr 2009

Researchers delve into blood cell generation process

These new insights represent an important contribution to future clinical therapeutic approaches.

1 Apr 2009

Quantum Immunologics announces the filing of two important provisional patent applications

Quantum Immunologics, Inc. (QI), a Florida-based company specializing in cancer immunotherapy, has recently filed two provisional patent applications relating to their work in cancer immunotherapy.

31 Mar 2009

Study examines drug delivery systems activated by light

A study published in a special issue of Photochemistry and Photobiology examines the emerging practice of drug delivery systems which use the application of light to activate medications in the body.

30 Mar 2009

A genetic technique to distinguish benign moles from malignant melanomas

A UCSF research team has developed a technique to distinguish benign moles from malignant melanomas by measuring differences in levels of genetic markers.

30 Mar 2009

New tool in the radiography approach will assist in earlier detection of asbestos-related diseases

Michael Harbut, M.D., MPH, co-director of the National Center for Vermiculite and Asbestos-Related Cancers (NCVAC) at the Barbara Ann Karmanos Cancer Institute in Detroit, MI, and chief of the Center for Occupational and Environmental Medicine Wayne State University, announced the use of a new technology to aid in the diagnosis of asbestos-related lung disease.

30 Mar 2009

New marker for breast cancer metastasis

Researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have identified a new marker for breast cancer metastasis called TMEM, for Tumor Microenvironment of Metastasis.

30 Mar 2009

Twin nanoparticle shown effective at targeting, killing breast cancer cells

A team of investigators at Brown University has developed a novel way to treat a class of breast cancer cells. The team has created twin nanoparticles that specifically targets the Her-2 tumor cell and unload a cancer-fighting drug directly into it. The result is a boost in antitumor activity while minimizing side effects. The findings of this study have been published in the Journal of the American Chemical Society.

26 Mar 2009

New approach to prostate cancer detection - Sarcosine may distinguish between slow-growing and aggressive prostate cancers

On Friday 20 March, US researcher Dr. Chris Beecher from the University of Michigan gave a well attended lecture about sarcosine, an N-methyl derivative of the amino acid glycine, at the 24th Annual EAU Congress in Stockholm, Sweden.

25 Mar 2009